DUBLIN--(BUSINESS WIRE)--The "Global Stem Cell Therapy Market by Type (Allogeneic, Autologous), Therapeutic Application (Musculoskeletal, Wound & Injury, CVD, Autoimmune & Inflammatory), Cell Source (Adipose tissue, Bone Marrow, Placenta/Umbilical Cord) - Forecasts to 2026" report has been added to ResearchAndMarkets.com's offering.
The global stem cell therapy market is projected to reach USD 401 million by 2026 from USD 187 million in 2021, at a CAGR of 16.5% during the forecast period.
Growth in this market is majorly driven by the increasing investment in stem cell research and the rising number of GMP-certified stem cell manufacturing plants. However, factors such as ethical concerns and the high cost of stem cell research and manufacturing process likely to hinder the growth of this market.
The allogeneic stem cell therapy segment accounted for the highest growth rate in the stem cell therapy market, by type, during the forecast period
The stem cell therapy market is segmented into allogeneic and autologous stem cell therapy. Allogeneic stem therapy segment accounted for the largest share of the stem cell therapy market. The large share of this segment can be attributed to the lesser complexities involved in manufacturing allogeneic-based therapies.
This segment is also expected to grow at the highest growth rate due to the increasing number of clinical trials in manufacturing allogeneic-based products.
Bone Marrow-derived MSCs segment accounted for the highest CAGR
Based on the cell source from which stem cells are obtained, the global stem cell therapy market is segmented into four sources. These include adipose tissue-derived MSCs (mesenchymal stem cells), bone marrow-derived MSCs, placenta/umbilical cord-derived MSCs, and other cell sources (which include human corneal epithelium stem cells, peripheral arterial-derived stem cells, and induced pluripotent stem cell lines).
The bone marrow-derived MSCs segment is expected to witness the highest growth rate during the forecast period, owing to an increasing number of clinical trials focused on bone marrow-derived cell therapies and the rising demand for these cells in blood-related disorders.
Asia Pacific: The fastest-growing country in the stem cell therapy market
The stem cell therapy market is segmented into North America, Europe, Asia Pacific, RoW. The stem cell therapy market in the Asia Pacific region is expected to grow at the highest CAGR during the forecast period.
Factors such as the growing adoption of stem cell-based treatment in the region and the growing approval & commercialization of stem cell-based products for degenerative disorders drive the growth of the stem cell therapy market in the region.
Market Dynamics
Drivers
- Availability of Funding for Stem Cell Research
- Increasing GMP-Certification Approvals for Cell Therapy Production Facilities
- Increasing Clinical Trials for Stem Cell Based-Therapies
Restraints
- Ethical Concerns Related to Embryonic Stem Cells
- High Cost of Cell-Based Research
Opportunities
- The Emergence of IPSCs as an Alternative to ESCs
- Growing Demand for Cell & Gene Therapies
Challenges
- Technical Limitations
Companies Mentioned
- AlloSource
- Anterogen
- Athersys
- BioRestorative Therapies
- BrainStorm Cell Therapeutics
- Cellular Biomedicine Group
- Corestem
- Holostem Terapie Avanzate S.r.l
- Hope Biosciences
- JCR Pharmaceuticals
- Kangstem Biotech
- MEDIPOST
- Mesoblast
- NuVasive
- Orthofix
- Personalized Stem Cells
- Pharmicell
- Pluristem Therapeutics
- Regrow Biosciences
- RTI Surgical
- Smith & Nephew
- Stempeutics Research
- Takeda Pharmaceutical Company
- ViaCyte
For more information about this report visit https://www.researchandmarkets.com/r/qiagh1
